Key clinical point: About one-third of overweight patients with nonalcoholic fatty liver disease or nonalcoholic steatohepatitis slimmed down after a weight-loss intervention, but about 20% gained weight back.
Major finding: About 34% of patients had 5% or more weight loss, while 20.2% regained weight back up to baseline or greater over about 2 years of follow-up.
Study details: A report from the ongoing prospective, observational TARGET-NASH study including 2,037 nonalcoholic fatty liver disease or nonalcoholic steatohepatitis patients with a body mass index of at least 25 kg/m2.
Disclosures: The study is sponsored by TARGET PharmaSolutions. Dr. Malespin reported disclosures with Gilead (speaker board), Intercept (speaker board, advisory committee), and TARGET PharmaSolutions (research grant paid to institution).
Malespin MH et al. The Liver Meeting 2019, Abstract 240.